News and Updates

Oasis BIO2024

June 5-9, 2024 San Diego

Partnering

AASLD Meeting

November 15-19, 2024 San Diego

Presented Abstract

First-in-human phase 1 study of the safety and pharmacodynamic effects of OA-235i, a PAR2
pepducin, in adults with metabolic-associated steatotic liver disease (MASLD) and steatohepatitis (MASH)

MASH - TAG

January 9-11, 2025 Park City, Utah

Presented Distinquished Oral Presentation on First-in-human phase 1 study of the safety and pharmacodynamic effects of OA-235i, a PAR2 Pepducin in adults with MASLD and MASH